[Skip to Content]
[Skip to Content Landing]
March 8, 1952


Author Affiliations

From the Ziskind Research Laboratories, New England Center Hospital, and the Department of Medicine, Tufts College Medical School.

JAMA. 1952;148(10):844-845. doi:10.1001/jama.1952.62930100002014a

Earlier clinical experience with partially purified corticotropin indicated that the purified preparation was somewhat more effective therapeutically than a standard preparation in equivalent amounts.1 The material, which had been purified using cellulose,2 assayed 20 U. S. P. units per milligram by the Sayers rat test3 but was judged to have a clinical potency of 30 units per milligram. Subsequent improvement in the method used in this laboratory for purification of corticotropin4 has permitted clinical use of a considerably more potent preparation. The purified corticotropin that was obtained in good yield using oxycellulose contained 80 units per milligram by bioassay. The clinical effectiveness of an aqueous solution, as judged from the dose requirements in 18 patients (table 1), suggested the therapeutic potency was about 150 units per milligram. The average daily dose was 0.6 mg. (48 units).

Purified corticotropin was administered by subcutaneous injection and was given

First Page Preview View Large
First page PDF preview
First page PDF preview